Related Experiment Videos
Decoding the causes of ischemic stroke despite ongoing oral anticoagulation and their clinical impact: the ASPERA-R
Federico De Santis1, Matteo Foschi1,2, Francesca Gabriele1
1Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, Via Vetoio Snc, 67100, L'Aquila, Italy.
Background:
Oral anticoagulants (OACs), including vitamin K antagonists and direct OACs, reduce stroke risk in atrial fibrillation (AF), yet breakthrough ischemic stroke still occurs in 1-2% of patients annually despite adequate therapy. The mechanisms underlying these events remain unclear. We aimed to identify potential causes of breakthrough ischemic stroke and assess their impact on outcomes, with a focus on drug interactions.
Methods:
ASPERA-R is a multicenter retrospective study including patients with ischemic stroke despite ongoing OAC therapy for AF (February 2020-February 2025). Ongoing treatment was defined by DOAC last intake within 48 h or therapeutic INR levels for VKAs. Potential causes included interacting drugs, active cancer, and competing etiologies. Ninety-day outcomes were compared between patients with and without ≥ 1 potential cause using adjusted Cox regression. Inverse probability-weighted analyses (IPW) evaluated the impact of interacting drugs.
Results:
Among 1649 patients (median age 80.4 years [IQR 73.2-85.6]; 860 [52.2%] female), most were on DOACs (1275; 77.3%), and 724 (43.9%) had ≥ 1 potential cause. Interacting drugs were identified in 28.4%, competing etiologies in 24.3%, and cancer in 4.4% cases. Patients with one or more potential cause had a higher risk of recurrent ischemic stroke at 90 days (HR 2.04, 95% CI 1.18-3.53) compared with those without, with no differences in other outcomes. In the IPW analyses, interacting drugs were associated with increased myocardial infarction risk (HR 3.26, 95% CI 1.30-8.17).
Conclusions:
Potential causes are identifiable in about half of breakthrough strokes and are associated with higher risk of recurrence compared with those without. Improved detection and management of these factors may reduce recurrence risk, warranting individualized approaches.
Insights
Breakthrough strokes in atrial fibrillation patients on anticoagulants often have identifiable causes like drug interactions. Recognizing these factors is key to reducing recurrent stroke risk.
Area of Science:
- Cardiology
- Neurology
- Pharmacology
Background:
- Oral anticoagulants (OACs) are crucial for stroke prevention in atrial fibrillation (AF).
- Despite OAC therapy, 1-2% of AF patients experience breakthrough ischemic strokes annually.
- Mechanisms behind these strokes, especially drug interactions, require further investigation.
Purpose of the Study:
- Identify potential causes of breakthrough ischemic strokes in AF patients on OACs.
- Assess the impact of these causes on patient outcomes, focusing on drug interactions.
- Evaluate the association between interacting drugs and adverse cardiovascular events.
Main Methods:
- ASPERA-R: A multicenter retrospective study of AF patients with ischemic stroke despite OAC therapy.
- Included patients on direct oral anticoagulants (DOACs) or vitamin K antagonists (VKAs).
- Analyzed potential causes: interacting drugs, cancer, competing etiologies; assessed 90-day outcomes using Cox regression and IPW.
Main Results:
- Nearly half (43.9%) of 1649 patients had at least one potential cause for stroke.
- Interacting drugs (28.4%) and competing etiologies (24.3%) were most common.
- Potential causes correlated with a 2-fold increased risk of recurrent ischemic stroke (HR 2.04).
Conclusions:
- Identifiable causes contribute to approximately half of breakthrough strokes in AF patients.
- These factors are linked to a higher risk of recurrent ischemic stroke.
- Individualized management strategies focusing on drug interactions and other causes are needed to reduce recurrence.
Related Concept Videos
Ischemic Stroke l: Introduction
Acute Coronary Syndrome III: Diagnostic Studies
Atherosclerosis III: Management
Atherosclerosis IV: Nursing Management
Ischemic Stroke ll: Pathophysiology
Aneurysm II: Clinical Manifestations and Diagnostic Studies